Clinical Trial

Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer

Study acronym: PICC-3
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The PICC-3 study is a multicentre, single-arm, phase II trial evaluating toripalimab plus celecoxib in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer. The trial uses a response-adapted treatment strategy, whereby patients with clinical complete response (cCR) after therapy may enter a non-operative management pathway, while patients without cCR proceed to surgery. Response assessment is based on imaging, endoscopy, biopsy evaluation, and ctDNA analysis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-28.
Trial Details
NCT Number NCT06903858
Lead Sponsor Sun Yat-sen University
Conditions Colorectal Cancer, Microsatellite Instability High, Mismatch Repair Deficiency
Enrollment 105 participants
Start Date 2025-06-01
Primary Completion 2028-04-01 (estimated)
Study Completion 2031-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-22